AES 2022
Long-term Treatment with Ganaxolone for Seizures Associated with CDKL5 Deficiency Disorder: 1-year Minimum Open-label Extension Follow-up
Pharmacokinetics, Pharmacodynamics, and Safety Study of Intravenous Ganaxolone in Healthy Adult Volunteers
Pharmacokinetics of Co-administered Ganaxolone and Cannabidiol in Healthy Adults
AES 2021
Longitudinal Relationship Between Seizure Burden and Developmental Progression and the Implications on Quality of Life in Children with CDKL5 Deficiency Disorder
Aggregated Safety and Tolerability Experience from the Ganaxolone Development Program
Extended Duration Safety and Efficacy of Adjunctive Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder: 8-Month Minimum Open-Label Extension Follow-up
Ganaxolone Treatment in Patients with CDKL5 Deficiency Disorder with Comorbid Lennox-Gastaut Syndrome: A Post-hoc Analysis from the Marigold Study
Utilization of Quantitative EEG Spectral Analysis to Characterize IV Ganaxolone PK/PD Properties in Refractory Status Epilepticus (RSE)
Phase 2 Open-Label Clinical Study Evaluating Oral Ganaxolone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex
Effect of Ganaxolone on Quality of Life in Children with CDKL5 Deficiency Disorder
IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: Two Case Presentations
Phase 2, Placebo-Controlled Clinical Study of Oral Ganaxolone in PCDH19-Clustering Epilepsy (the Violet Study)
AES 2020
Ganaxolone Significantly Reduces Major Motor Seizures Associated With CDKL5 Deficiency Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (Marigold Study)
Pharmacokinetic-Pharmacodynamic Analysis of Oral Ganaxolone in Patients with CDKL5 Deficiency Disorder: Results From the Marigold Study
Intravenous Ganaxolone for the Treatment of Refractory Status Epilepticus: Results From an Open-Label, Dose-Finding, Phase 2 Study
IV Ganaxolone in Pediatric Super Refractory Status Epilepticus: A Single Patient Case Study
Ganaxolone Mechanism of Action and Pharmacology
Effect of Ganaxolone on Seizure Frequency Across Subpopulations of Patients With CDKL5 Deficiency Disorder: Subgroup Analyses of the Marigold Study
Status Epilepticus: Inpatient Burden of Illness and Association with Disease Severity
Treatment of Super Refractory Status Epilepticus Using Intravenous Ganaxolone in a Patient with Lennox-Gastaut Syndrome and Angelman Syndrome
A Double-Blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus (RAISE)
Extended Duration Safety and Efficacy of Ganaxolone for the treatment of CDKL5 Deficiency Disorder: Preliminary Open-Label Extension Analysis (Marigold Study)
AES 2019
Intravenous Ganaxolone Achieves Rapid and Does-Dependent Sustained Improvement in EEG Seizure Burden in Patients with Refractory with Refractory Status Epilepticus (marinuspharma.com)
Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus
Population Pharmacokinetic/Pharmacodynamic Modeling of the Electroencephalographic Effects of Ganaxolone in Healthy Subjects
AES 2018
Ganaxolone in CDKL5 Deficiency Disorder: Open-Label Phase 2a Results and Ongoing Pivotal Phase 3 Study Design
Long-term, Durable Seizure Frequency Reduction in Children with CDKL5 Deficiency Disorder (CDD) Treated with Ganaxolone